Kali-Extracts and Nouveau Anticipate $5 Million In Potential Revenue From Hemp Cultivation And Extraction Venture
December 31 2018 - 9:17AM
InvestorsHub NewsWire
Kali-Extracts and Nouveau Anticipate $5 Million In Potential
Revenue From Hemp Cultivation And Extraction Venture
DALLAS, TX --
December 31, 2018 -- InvestorsHub NewsWire
-- Kali, Inc. (dba/Kali-Extracts, Inc.)
(USOTC:
KALY) (“KALY”) and Nouveau Life Pharmaceuticals, Inc.
(dba/Nouveau, Inc) (USOTC:
NOUV) (“NOUV”) today announced the two companies anticipate up
to $5 million in revenue from their hemp cultivation and extraction
venture. The two companies recently announced an agreement to
expand NOUV’s current cultivation operations to include 100
adjacent acers dedicated to growing hemp under the new Farm Bill
legalizing hemp farming just signed into law by President
Trump. KALY will construct a CBD extraction facility on site
based on KALY’s patented extraction process. In addition to
the outdoor hemp cultivation, NOUV will build a state-of-the-art
greenhouse operation intended for the development of a proprietary
hemp cultivar. Industry sources, including a Forbes article
published today titled Cannabis Companies Expect Big Growth After Trump
Legalizes Hemp, indicate hemp farming could yield
$50,000 per acre from the combination of CBD extraction and other
uses of hemp. KALY and NOUV’s 100 acers hemp cultivation
operation could yield $5 million at that
rate.
KALY produces pharmaceutical grade
cannabis extracts that have been involved in multiple clinical
trials in addition to utilizing its patented cannabis extraction
process in the production of CBD infused nutrition and wellness
products to include its own Hemp4mula and CBD infused waters
produced by Puration, Inc. (USOTC:
PURA) (“PURA”).
NOUV has a cannabis cultivation operation
with facilities in the U.S. and Canada. NOUV’s objective in
the partnership announced today with KALY is to develop a
proprietary pharmaceutical grade hemp cultivar in addition to being
a source of hemp supply for a myriad of industries in what
management anticipates to be exploding demand in
2019.
KALY, NOUV and PURA are partners in a
joint venture named US Cannabis Health for the purpose of together
developing partnerships with pharmaceutical companies to develop
cannabis pharmaceuticals. US Cannabis Health recently
announced its first agreement with Generex Biotechnology, Corp.
(OTCQB:
GNBT).
To learn more about the KALY and NOUV
project announced today, follow developments online at www.kali-extracts.com.
Disclaimer/Safe
Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any
disease.
Kali,
Inc.
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Apr 2023 to Apr 2024